MedPath

PetVivo and Orthobiologic Innovations Partner to Advance Osteoarthritis Treatment for Pets

• PetVivo and Orthobiologic Innovations (OBI) are collaborating to advance clinical trials for Spryng with OsteoCushion Technology, a treatment for osteoarthritis in animals. • The trials will focus on managing joint issues in the elbows and stifles of canine patients, evaluating the injection of collagen-elastin hydrogel microparticles. • OBI's expertise will support the development, marketing, and expansion of Spryng, aiming to provide long-term relief and improve joint function in pets. • Spryng is designed to replicate the function of natural cartilage, offering a shock-absorbing matrix for damaged joints.

PetVivo Holdings, Inc., a biomedical company specializing in therapeutic medical devices for pets and equines, has announced a partnership with Orthobiologic Innovations (OBI), a research and development company focused on regenerative and sports medicine. The collaboration aims to advance clinical trials and commercialization of PetVivo's Spryng with OsteoCushion Technology, a veterinary device designed to treat osteoarthritis in animals.
The partnership will focus on conducting clinical trials of Spryng, particularly for managing joint issues in the elbows and stifles of canine patients. These studies will evaluate the injection of collagen-elastin hydrogel microparticles into the elbows of dogs with osteoarthritis and into the stifles of dogs that have undergone a tibial plateau leveling osteotomy (TPLO) procedure. OBI will also support additional studies planned for the coming year.

Spryng with OsteoCushion Technology

Spryng with OsteoCushion Technology is an intra-articular injectable veterinary device designed to address damaged cartilage in joints associated with lameness. According to PetVivo, the injection works by forming a shock-absorbing matrix that interacts with synovial fluid to mimic the structure and function of healthy joint cartilage. The microparticulate is composed of collagen, elastin, and a carbohydrate, creating a hydrated material with lubricating and viscoelastic properties similar to natural cartilage.

Expert Perspectives

Sherman O. Canapp Jr., DVM, MS, CCRT, DACVS (SA), DACVSMR, president and CEO of OBI, stated, "As a double-boarded orthopedic and sports medicine small animal veterinarian, my primary focus is on returning patients to full function as quickly and safely as possible using innovative evidence-based approaches. I look forward to working with PetVivo and their Spyrng with Osteocushion Technology to deliver long-term relief from the pain associated with osteoarthritis, by addressing the underlying structural issues, so that we can restore mobility and improve patient joint function over a longer period."
John Lai, PetVivo president and CEO, added, "We chose to team with OBI because they are consistently on the frontline of new medical technologies. Sherman and Debra bring impressive knowledge and experience, particularly from their work in helping to develop new medical products that focus on the physical health of small animals and arthritis interventions. This makes their team a great fit with furthering our clinical trials and expanding the market adoption of Spryng. They will help us build product awareness and accelerate the growth and the expansion of our market reach across the US."

Osteoarthritis in Animals

Osteoarthritis is a degenerative joint disease characterized by the gradual breakdown of articular cartilage, leading to thinning of the cartilage, joint effusion, and osteophyte formation. The condition can result from trauma, infections, immune-related disorders, or developmental malformations. Symptoms include lameness, joint swelling, muscle wasting, and fibrosis around the joint capsule.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Loyal's LOY-002 Receives FDA's RXE Acceptance for Canine Lifespan Extension

Loyal's LOY-002, a drug aimed at extending the healthy lifespan of senior dogs, has received acceptance from the FDA for its Reasonable Expectation of Effectiveness (RXE).
The drug targets age-related metabolic dysfunction in dogs aged 10 years and older, weighing at least 14 lbs, with the goal of improving their quality of life.

Cytophage and Orthopaedic Innovation Centre Partner to Advance Phage Therapy for Prosthetic Joint Infections

Cytophage Technologies partners with the Orthopaedic Innovation Centre to launch Manitoba's first Phage Clinical Treatment Program, targeting antibiotic-resistant prosthetic joint infections.
The collaboration aims to validate phage therapy as a viable treatment option, potentially reducing healthcare costs and expanding patient access to innovative solutions.

Doron Therapeutics Secures $11M to Advance MOTYS for Knee Osteoarthritis into Phase 3 Trial

Doron Therapeutics has raised $11 million in Series A funding to support a Phase 3 clinical trial of MOTYS, a novel intra-articular biologic drug for symptomatic knee osteoarthritis.
MOTYS, derived from placental tissue, aims to provide anti-inflammatory, anti-catabolic, and pro-anabolic effects through growth factors, offering a potential alternative to corticosteroids and hyaluronic acid.

Gene Therapy for Osteoarthritis Shows Promising Results in Phase 1 Trial

A gene therapy developed at Baylor College of Medicine, PCRX-201, is showing promising results in Phase 1 clinical trials for osteoarthritis.
The therapy utilizes a high-capacity adenovirus vector to deliver interleukin-1 receptor antagonist (IL-1Ra) to reduce inflammation in the knee joint.

Calviri Launches Clinical Trial of Cancer Vaccine for Early-Stage Hemangiosarcoma in Dogs

Calviri has initiated a clinical trial for its investigational immunotherapy vaccine in dogs with early-stage hemangiosarcoma (HSA).
The SOCH trial will assess if the vaccine, combined with standard treatment, can extend the lifespan of dogs with stage 1 or 2 HSA tumors.

Strategic Collaborations and Novel Therapies Advance Cancer and Brain Injury Treatment

AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors.
SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials.

Sparta Biomedical Initiates First-in-Human Trial of Ormi Device for Knee Osteoarthritis

Sparta Biomedical has commenced a first-in-human clinical trial for its Ormi device, a novel solution for focal knee lesions associated with osteoarthritis.
The study assesses the safety of Ormi in patients with knee pain resulting from articular cartilage loss in the femoral condyle, with ongoing monitoring for patient recovery.

Loyal's STAY Study: Clinical Trial Aims to Extend Healthy Lifespan in Senior Dogs

Loyal's STAY study is a nationwide clinical trial assessing a novel drug's ability to extend healthy lifespan in senior dogs, potentially delaying age-related metabolic dysfunction.
The double-blind, placebo-controlled trial involves 1,000 dogs and requires daily oral administration of the drug, with all costs covered by Loyal.

Clinical Trial Launched to Treat Cardiac Tumors in Dogs Using Propranolol

The Atlantic Veterinary College (AVC) at UPEI has initiated a clinical trial to evaluate propranolol for treating cardiac tumors in dogs.
Propranolol, a beta-blocker used in children for similar conditions, will be assessed for its ability to shrink tumors and improve the quality of life in dogs.

Loyal's Anti-Aging Drug for Senior Dogs Enters Clinical Trials, Aims to Extend Healthy Lifespan

Loyal's LOY-002, a novel anti-aging drug targeting metabolic health in senior dogs, has entered clinical trials, potentially extending their healthy lifespan.
The STAY study, involving over 1,000 dogs across 50+ vet clinics, will assess LOY-002's impact on lifespan and quality of life compared to a placebo over four years.

Reference News

[1]
Two organizations partner to develop research on veterinary device for osteoarthitis
dvm360.com · Sep 13, 2024

PetVivo partners with Orthobiologic Innovations (OBI) to pursue clinical trials of Spryng with OsteoCushion Technology f...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy